News

For the year ended December 31, 2008, the company reported a net loss of $22.61 million, or $0.42 per share, compared to a net loss of $24.2 million,

Endo Pharmaceuticals, a developer and marketer of branded and generic prescription pharmaceuticals, has reported the successful completion of the tender offer by its wholly owned subsidiary, BTB Purchaser,

For the full year 2008, the company reported a net loss of $64.75 million, or $4.03 per share, compared to a net loss of $29.85 million, or $2.19

For the year ended December 31, 2008, the company posted a net loss of C$41.39 million, or C$0.45 per share, compared to a net loss of C$38.92 million,

Indian scientists from the past decade, under fewer restrictions, pushed ahead with their own research. “The future impact that I see of the reversal of the Bush administration

Under the terms of the agreement, Arabian Medical Marketing (AMCO) will provide direct sales and service support for Intelligent Hospital Systems’s (IH Systems’s) Robotic IV Automation (RIVA) system

Charles Wilhelm, president and COO of Karl Storz, said: “Karl Storz has had a marketing agreement with Global Care Quest since 2006. Our acquisition of the company now

The program is intended to produce therapeutic molecules for the treatment of inflammatory airway diseases including rhinitis, asthma and chronic obstructive pulmonary disease (COPD). The trial data showed

Morphotek, a subsidiary of Eisai Corporation of North America, has reported that the FDA has agreed to and approved the design of a single, pivotal, Phase III clinical